Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomised trials: a systematic review and network meta-analysis.
Tiago V Pereira,Pakeezah Saadat,Pavlos Bobos,Samir M Iskander,Nicolas S Bodmer,Martina Rudnicki,Henry Dan Kiyomoto,Thais Montezuma,Matheus O Almeida,Rishi Bansal,Pai-Shan Cheng,Jason W Busse,Alex J Sutton,Peter Tugwell,Gillian A Hawker,Peter Jüni,Bruno R da Costa
{"title":"Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomised trials: a systematic review and network meta-analysis.","authors":"Tiago V Pereira,Pakeezah Saadat,Pavlos Bobos,Samir M Iskander,Nicolas S Bodmer,Martina Rudnicki,Henry Dan Kiyomoto,Thais Montezuma,Matheus O Almeida,Rishi Bansal,Pai-Shan Cheng,Jason W Busse,Alex J Sutton,Peter Tugwell,Gillian A Hawker,Peter Jüni,Bruno R da Costa","doi":"10.1016/j.joca.2024.08.014","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\r\nTo quantify the effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis through a systematic review and Bayesian random-effects network meta-analysis.\r\n\r\nDESIGN\r\nWe searched CENTRAL and regulatory agency websites (inception-2023) for large, English-language, randomised controlled trials (RCTs) (≥100 patients/group) examining any intra-articular intervention.\r\n\r\nPRIMARY OUTCOME\r\npain intensity.\r\n\r\nSECONDARY OUTCOMES\r\nphysical function and safety outcomes. Pain and function outcomes were analyzed at 2,6,12,24, and 52 weeks post-randomization, and presented as standardized mean differences (SMDs) (95% credible intervals, 95%CrI). The prespecified minimal clinically important between-group difference (MID) was -0.37 SMD. Safety outcomes were presented as odds ratios (OR) (95%CrI).\r\n\r\nFINDINGS\r\nAmong 57 RCTs (22,795 participants) examining 18 intra-articular interventions, usual care or placebo, treatment effects were larger in high-risk-of-bias trials (n=35) than low/unclear-risk-of-bias trials (n=22). In the main analysis (excluding high-risk-of-bias trials), triamcinolone had the highest probabilities of reaching the MID at weeks 2-6 (75.3% and 90%, respectively) with corresponding SMDs of -0.48 (95%CrI,-0.85 to -0.10) and -0.53 (95%CrI,-0.79 to -0.27) compared to placebo. Tr14/Ze14 homeopathic product showed therapeutic potential at week 6 compared to placebo (SMD:-0.42, 95%CrI,-0.71 to -0.11, 63.5% probability of reaching the MID). Hyaluronic acid had higher risk of dropouts due to adverse events (OR:2.01, 95%CrI,1.08 to 3.77) and serious adverse events (OR:1.86, 95%CrI,1.16 to 3.03) than placebo.\r\n\r\nCONCLUSION\r\nTriamcinolone had the highest probabilities to have a treatment effect beyond the MID at weeks 2-6. Large RCTs with lower risk of bias do not support the notion that 16 other intra-articular interventions assessed improve pain or function beyond placebo effects in knee or hip OA. Lack of evidence of long-term effectiveness underscores the need for further research beyond 24-52 weeks.","PeriodicalId":19654,"journal":{"name":"Osteoarthritis and Cartilage","volume":null,"pages":null},"PeriodicalIF":7.2000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoarthritis and Cartilage","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.joca.2024.08.014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
OBJECTIVE
To quantify the effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis through a systematic review and Bayesian random-effects network meta-analysis.
DESIGN
We searched CENTRAL and regulatory agency websites (inception-2023) for large, English-language, randomised controlled trials (RCTs) (≥100 patients/group) examining any intra-articular intervention.
PRIMARY OUTCOME
pain intensity.
SECONDARY OUTCOMES
physical function and safety outcomes. Pain and function outcomes were analyzed at 2,6,12,24, and 52 weeks post-randomization, and presented as standardized mean differences (SMDs) (95% credible intervals, 95%CrI). The prespecified minimal clinically important between-group difference (MID) was -0.37 SMD. Safety outcomes were presented as odds ratios (OR) (95%CrI).
FINDINGS
Among 57 RCTs (22,795 participants) examining 18 intra-articular interventions, usual care or placebo, treatment effects were larger in high-risk-of-bias trials (n=35) than low/unclear-risk-of-bias trials (n=22). In the main analysis (excluding high-risk-of-bias trials), triamcinolone had the highest probabilities of reaching the MID at weeks 2-6 (75.3% and 90%, respectively) with corresponding SMDs of -0.48 (95%CrI,-0.85 to -0.10) and -0.53 (95%CrI,-0.79 to -0.27) compared to placebo. Tr14/Ze14 homeopathic product showed therapeutic potential at week 6 compared to placebo (SMD:-0.42, 95%CrI,-0.71 to -0.11, 63.5% probability of reaching the MID). Hyaluronic acid had higher risk of dropouts due to adverse events (OR:2.01, 95%CrI,1.08 to 3.77) and serious adverse events (OR:1.86, 95%CrI,1.16 to 3.03) than placebo.
CONCLUSION
Triamcinolone had the highest probabilities to have a treatment effect beyond the MID at weeks 2-6. Large RCTs with lower risk of bias do not support the notion that 16 other intra-articular interventions assessed improve pain or function beyond placebo effects in knee or hip OA. Lack of evidence of long-term effectiveness underscores the need for further research beyond 24-52 weeks.
期刊介绍:
Osteoarthritis and Cartilage is the official journal of the Osteoarthritis Research Society International.
It is an international, multidisciplinary journal that disseminates information for the many kinds of specialists and practitioners concerned with osteoarthritis.